Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06084104 · ClinicalTrials.gov registry record · Phase 1
DZD9008 PK Study in Hepatic Impairment Subjects
A Phase 1 study, sponsored by Dizal Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT06084104 is a Phase 1 study that has completed, run by Dizal Pharmaceuticals. The registered enrollment target is 17 participants.
The verdict
NCT06084104, a Phase 1 study, has completed, sponsored by Dizal Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
This study will investigate the pharmacokinetics, safety, and tolerability of DZD9008 in subjects with hepatic impairment compared to subjects with normal hepatic function
Interventions
- DRUG DZD9008
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2023-10-17 |
| Est. Completion | 2024-10-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06084104
The ClinicalTrials.gov registry entry for NCT06084104 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dizal Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DZD9008 is the first listed.
NCT06084104 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06084104 about?
NCT06084104 is a clinical study titled "DZD9008 PK Study in Hepatic Impairment Subjects". This study will investigate the pharmacokinetics, safety, and tolerability of DZD9008 in subjects with hepatic impairment compared to subjects with normal hepatic function
What is the current status of trial NCT06084104?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2023-10-17. Estimated completion is 2024-10-23.
What interventions are being tested in trial NCT06084104?
The interventions under investigation include: DZD9008 (DRUG).
Who is sponsoring clinical trial NCT06084104?
This trial is sponsored by Dizal Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.